Stockscreener 앱 받기
4.0126
0.57%
0.0226
시간 외 거래:
4.01
-0.0026
-0.06%
전일 마감가:
$3.99
열려 있는:
$3.81
하루 거래량:
5,190
Relative Volume:
0.27
시가총액:
$6.09M
수익:
$2.54M
순이익/손실:
$-4.13M
주가수익비율:
-1.3884
EPS:
-2.89
순현금흐름:
$-4.11M
1주 성능:
+9.63%
1개월 성능:
+6.58%
6개월 성능:
+7.87%
1년 성능:
+24.86%
1일 변동 폭
$3.81
$4.02
1주일 범위
$3.58
$4.08
52주 변동 폭
$2.78
$5.20
Xenetic Biosciences Inc Stock (XBIO) Company Profile
명칭
Xenetic Biosciences Inc
전화
781-778-7720
주소
945 CONCORD ST., FRAMINGHAM, MA
XBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| XBIO | 4.0126 | 6.09M | 2.54M | -4.13M | -4.11M | -2.89 |
| VRTX | 450.37 | 115.10B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.07B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.20B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 25.09B | 3.30B | -501.07M | 1.03B | 11.54 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-01-08 | 개시 | Maxim Group | Buy |
Xenetic Biosciences Inc 주식(XBIO)의 최신 뉴스
XBIOXenetic Biosciences, Inc. Latest Stock News & Market Updates - StockTitan
Xenetic presents preclinical data on DNase I with CAR T cells in murine model - TipRanks
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis - AccessWire
Xenetic Bio's DNase I + CAR T Cell Therapy Shows Breakthrough in Melanoma Treatment | XBIO Stock News - StockTitan
Xenetic Biosciences Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Xenetic reports Q3 EPS (28c) vs. (69c) last year - TipRanks
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results - AccessWire
Xenetic Bio Q3: R&D Costs Drop 64% as DNase Cancer Program Advances | $6.8M Cash | XBIO Stock News - StockTitan
Xenetic Biosciences: Q3 Earnings Snapshot - Houston Chronicle
Xenetic presents preclinical data on DNase platform technology - TipRanks
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models - Oil City Derrick
Xenetic's DNase I Breakthrough Boosts Cancer Immunotherapy Efficacy in Preclinical Study | XBIO Stock News - StockTitan
Xenetic Biosciences Extends Research Collaboration with The Scripps Research Institute - Defense World
Xenetic extends research collaboration with Scripps Research Institute - TipRanks
Xenetic Biosciences Expands Collaboration for Cancer Treatment - TipRanks
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform - AccessWire
Xenetic Biosciences announces board member changes - Investing.com India
Xenetic Biosciences announces board member changes By Investing.com - Investing.com UK
Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Grows By 460.0% - Defense World
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 - AccessWire
SEC Form S-3 filed by Xenetic Biosciences Inc. - Quantisnow
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform - AccessWire
Secondary Progressive Multiple Sclerosis Drug Market to Expand with Significant CAGR by 2034 |AB Science SA, Actelion Lt – IndiaPolitics.com - IndiaPolitics.com
Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Drops By 50.0% - Defense World
Xenetic Biosciences Inc (NASDAQ:XBIO) Sees Significant Decline in Short Interest - Defense World
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference - Kansas City Star
Q3 2024 Earnings Estimate for Xenetic Biosciences Inc (NASDAQ:XBIO) Issued By HC Wainwright - Defense World
XBIO Stock Earnings: Xenetic Biosciences Meets EPS, Beats Revenue for Q2 2024 - MSN
Xenetic Biosciences (NASDAQ:XBIOW) Stock Price Up 33.9% - Defense World
Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates - MSN
Xenetic Biosciences (NASDAQ:XBIO) Earns “Neutral” Rating from HC Wainwright - Defense World
Xenetic Biosciences Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line - Simply Wall St
Xenetic Biosciences (NASDAQ:XBIO) Releases Earnings Results, Hits Estimates - Defense World
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update - Markets Insider
Xenetic Biosciences: Q2 Earnings Snapshot - CTPost
Xenetic Biosciences Inc (XBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
3.55%
자본화:
|
볼륨(24시간):